Back
Aclaris Therapeutics Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
19
ACRS
Aclaris Therapeutics
Last Price:
1.11
Seasonality Move:
-7.32%
Buy
51
ALNY
Alnylam Pharmaceuticals
Last Price:
242.97
Seasonality Move:
20.36%
Sell
19
Aclaris Therapeutics (ACRS)
is a Sell
Is Aclaris Therapeutics a Buy, Sell or Hold?
- The current Aclaris Therapeutics [ACRS] share price is $1.11. The Score for ACRS is 19, which is 62% below its historic median score of 50, and infers higher risk than normal.
- ACRS is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
Buy
51
Alnylam Pharmaceuticals (ALNY)
is a Buy
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $247.00. The Score for ALNY is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.
- ALNY is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
ACRS Stock Price Chart
What is Aclaris Therapeutics's stock price today?
-
The Aclaris Therapeutics share price today is $1.11
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ACRS is experiencing selling pressure, which indicates risk of future bearish movement.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $247.00
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight selling pressure.
ACRS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.01 | Buy |
| Relative Strength Index (14 RSI): | 46.6 | Sell |
| Chaikin Money Flow: | -670130 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (1.03 - 1.19) | Buy |
| Bollinger Bands (100): | (1.11 - 1.27) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 20.83 | Buy |
| Relative Strength Index (14 RSI): | 90.67 | Buy |
| Chaikin Money Flow: | -365678 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (135.21 - 198.95) | Buy |
| Bollinger Bands (100): | (137.63 - 173.99) | Buy |
ACRS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.17 | Sell |
| 20-day SMA: | 1.11 | Sell |
| 50-day SMA: | 1.17 | Sell |
| 200-day SMA: | 2.19 | Sell |
| 8-day EMA: | 1.16 | Sell |
| 20-day EMA: | 1.14 | Sell |
| 50-day EMA: | 1.17 | Sell |
| 200-day EMA: | 2.78 | Sell |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 198.72 | Buy |
| 20-day SMA: | 171.59 | Buy |
| 50-day SMA: | 157.67 | Buy |
| 200-day SMA: | 165.81 | Buy |
| 8-day EMA: | 210.85 | Buy |
| 20-day EMA: | 183.04 | Buy |
| 50-day EMA: | 165.87 | Buy |
| 200-day EMA: | 167.34 | Buy |
Aclaris Therapeutics Earnings Growth & ACRS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.32 per share, an increase next quarter of $0.04 per share, an increase this year of $0.86 per share, and an increase next year of $0.23 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.12 per share, a decrease this year of $0.46 per share, and an increase next year of $1.83 per share.
Aclaris Therapeutics Technical Analysis
| Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Jun 13 | Jun 14 | Jun 17 | Jun 18 | Jun 20 | Jun 21 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun | ||||||||||
| 13 | 14 | 17 | 18 | 20 | 21 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||